Evidence map›Paper›PMID 41318546›Full record

ArticleHuman genomics2025

Multi-region spatial transcriptomics reveals region specific differences in response to amyloid beta (Aβ) plaque induced changes in Alzheimer's disease (AD).

Odmaa Bayaraa, Michael Aksu, Evon DeBose-Scarlett, Emily Hocke, Vaibhav Jain, Shih-Hsiu J Wang, Dianne A Cruz, Simon G Gregory

Abstract read
In one paragraph

Article in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Odmaa BayaraaDuke University Program in Genetics and Genomics, Duke University School of Medicine, Durham, NC, 27710, USA.
Michael AksuDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, 27701, USA.
Evon DeBose-ScarlettDuke Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, 27710, USA.
Emily HockeDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, 27701, USA.
Vaibhav JainDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, 27701, USA.
Shih-Hsiu J WangDuke Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.
Dianne A CruzDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, 27701, USA.
Simon G GregoryDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, 27701, USA. simon.gregory@duke.edu.

Funding

Topographic, cell type and molecular pathway characterization ofAlzheimer's disease using single cell transcriptomics and epigenomicsU19AG060909 · NIA · ALLEN INSTITUTE · PI Jennie Leigh Close, Michael Hawrylycz · 2020 to 2026
$83.6M
Translational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergicsU19AG066567 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Christine L MacDonald · 2021 to 2026
$80.4M
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
Furthering scientific understanding of mechanisms underlying resilience to the effects of AD pathology by incorporating state of the art quantification of gliosis, inflammation, & synaptic toxicityU01AG006781 · NIA · UNIVERSITY OF WASHINGTON · PI CRANE, PAUL K, LARSON, ERIC B · 1986 to 2020
$39.3M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Amanda D. Boyd · 2020 to 2026
$29.0M
Research Education Component CoreP30AG072958 · NIA · DUKE UNIVERSITY · PI Heather E. Whitson · 2021 to 2026
$24.1M
National Institute on Aging (NIA) P30AG072958NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG072958NIA NIH HHS P50 AG005136NIA NIH HHS U01 AG006781NIA NIH HHS U19 AG060909NIA NIH HHS U19 AG066567
6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is the leading cause of dementia affecting 55 million people worldwide. The pathological hallmarks of AD, beta-amyloid (Aβ) plaques and neurofibrillary tangles (NFT), follow distinct stereotypical patterns of progression across brain regions and trigger a multicellular response that ultimately leads to neuronal loss and cognitive decline. Despite the uniform spread of Aβ plaque across the cortex during AD progression, different regions demonstrate varying levels of vulnerability and resilience to temporal Aβ plaque induced changes, such as NFT accumulation. There is a critical gap in our understanding of the cell types and molecular mechanisms that underlie these region-specific differences in resilience to Aβ plaque induced changes. In this study, we hypothesized that brain region and cell type specific transcriptional responses within the Aβ microenvironment, and more broadly within the grey matter, may contribute to this variation.

resultsWe carried out matched multi-region spatial transcriptomics and Aβ immunofluorescence staining from the entorhinal, occipito-temporal, dorsolateral prefrontal, and striate cortices from two individuals with Braak III and Thal 4 AD. Spatiotemporal comparisons of cell type proportions, gene expression, and cell-cell communication revealed differences in the vulnerability of somatostatin and somatostatin chondrolectin inhibitory neurons and the expression of endosomal and lysosomal trafficking and metallothionein genes within the Aβ plaque microenvironment. We also observed variations in blood-brain-barrier dysfunction, fibroblast growth factor signaling, and vascular impairment and repair related cell-cell communication networks within the grey matter across the four regions.

conclusionsOur results demonstrate the value of simultaneously profiling AD-omic and spatial modalities in multiple regions to elucidate how cortical region-specific differences contribute to selective vulnerability and resilience during neurodegeneration. These cortical region and Aβ microenvironment-specific transcriptional changes during AD neurodegeneration highlight the potential for spatially targeted therapeutic approaches.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesPlaque, AmyloidTranscriptomeAgedAged, 80 and overBrainFemaleHumansMaleNeurofibrillary TanglesAmyloid beta-PeptidesAlzheimer’s diseaseAβ plaquesCell type specificityNeocortexNeurofibrillary tanglesSelective vulnerabilitySpatial transcriptomics

Identifiers

PMID41318546
PMCPMC12772032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.